Find Reports
Select Report Type
Reimbursement Review
Displaying 626 - 650 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Blinatumomab (Blincyto) for Ph... | Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | PC0064-000 | |||
| Opdivo for Metastatic Melanoma... | Opdivo | Nivolumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0063-000 | |||
| Asfotase alfa | Strensiq | Asfotase alfa | Hypophosphatasia, pediatric-onset | List with criteria/condition | Complete | SR0443-000 | |||
| Denosumab (Drug Plan Submissio... | Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer | List with clinical criteria and/or conditions | Complete | SR0433-001 | |||
| Sacubitril/valsartan | Entresto | Sacubitril/valsartan | Heart failure, NYHA class II or III | List with clinical criteria and/or conditions | Complete | SR0447-000 | |||
| Ombitasvir/ paritaprevir/ rito... | Technivie | Ombitasvir/ paritaprevir/ ritonavir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | SR0444-000 | |||
| Filgrastim | Grastofil | Filgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | SE0446-000 | |||
| Deferiprone | Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | SR0448-000 | |||
| Elvitegravir/cobicistat/emtric... | Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | SR0449-000 | |||
| Jakavi for Polycythemia Vera -... | Jakavi | Ruxolitinib | Polycythemia vera | Reimburse with clinical criteria and/or conditions | Complete | PC0065-000 | |||
| Denosumab (Drug Plan Submissi... | Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from breast cancer | List with clinical criteria and/or conditions | Complete | SR0433-000 | |||
| Tolvaptan | Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | SR0435-000 | |||
| Galsulfase (Drug Plan Submissi... | Naglazyme | Galsulfase (Drug Plan Submission) | Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) | List with clinical criteria and/or conditions | Complete | SR0434-000 | |||
| Evolocumab | Repatha | Evolocumab | Primary hyperlipidemia; mixed dyslipidemia | List with clinical criteria and/or conditions | Complete | SR0441-000 | |||
| Fluticasone Furoate and Vilant... | Breo Ellipta | Fluticasone Furoate and Vilanterol (as trifenatate) | Asthma | List with clinical criteria and/or conditions | Complete | SR0442-000 | |||
| Fluticasone furoate | Arnuity Ellipta | Fluticasone furoate | Asthma | List with criteria/condition | Complete | SR0439-000 | |||
| Tiotropium / olodaterol | Inspiolto Respimat | Tiotropium / olodaterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | SR0436-000 | |||
| Riociguat | Adempas | Riociguat | Pulmonary arterial hypertension (WHO group 1) | List with clinical criteria and/or conditions | Complete | SR0438-000 | |||
| Peginterferon beta-1a | Plegridy | Peginterferon beta-1a | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | SR0440-000 | |||
| Apremilast | Otezla | Apremilast | Arthritis, psoriatic | List with criteria/condition | Complete | SR0437-000 | |||
| Zykadia for Metastatic Non-Sma... | Zykadia | Ceritinib | Metastatic Non-Small Cell Lung Cancer | Do not reimburse | Complete | PC0062-000 | |||
| Vectibix for mCRC – Details | Vectibix | Panitumumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0060-000 | |||
| Revlimid for Newly Diagnosed M... | Revlimid | Lenalidomide | Multiple Myeloma, newly diagnosed | Reimburse with clinical criteria and/or conditions | Complete | PC0061-000 | |||
| Dapagliflozin | Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | SR0428-000 | |||
| Ivacaftor | Kalydeco | Ivacaftor | Cystic fibrosis, R117H CFTR gating mutation | List with criteria/condition | Complete | SR0430-000 |
Health Technology Review
Displaying 576 - 600 of 600
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 626 - 650 of 2132
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| CADTH Pharmaceutical Reviews Update — Issue 39 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Triple Negative Breast Cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0024-000 | |||
| Deep Brain Stimulation Surgery Programs in Canada | Health Technology Review | Technology Review | Completed | HC0065-000 | |||
| Hybrid Operating Rooms Suites | Horizon Scan | Emerging Health Technologies | Completed | EH0121-000 | |||
| axicabtagene ciloleucel | Reimbursement Review | Complete | PG0293-000 | ||||
| CADTH Pharmaceutical Reviews Update — Issue 38 | Reimbursement Review | Pharmaceutical Review Update | |||||
| ravulizumab | Reimbursement Review | Complete | SR0740-000 | ||||
| An Overview of Pharmacogenomic Testing for Psychiatric Disorders | Horizon Scan | Emerging Health Technologies | Completed | EH0115-000 | |||
| Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0028-000 | |||
| RET fusion-positive non-small cell lung cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0026-000 | |||
| Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases | Health Technology Review | Summary with Critical Appraisal | Completed | RC1483-000 | |||
| CADTH Pharmaceutical Reviews Update — Issue 37 | Reimbursement Review | Pharmaceutical Review Update | |||||
| cemiplimab | Reimbursement Review | Complete | PC0260-000 | ||||
| finerenone | Reimbursement Review | Complete | SR0737-000 | ||||
| Chloroprocaine for Spinal or Epidural Anesthesia | Health Technology Review | Rapid Review | Completed | RC1482-000 | |||
| pegcetacoplan | Reimbursement Review | Complete | SR0748-000 | ||||
| Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer | Health Technology Review | Rapid Review | Completed | RC1481-000 | |||
| Overview of HTA Processes for Time-limited Recommendations | Health Technology Review | Environmental Scan | Completed | ES0377-000 | |||
| Alternative Therapies to Immunoglobulin for Guillain-Barré Syndrome | Health Technology Review | Rapid Review | Completed | RC1480-000 | |||
| amivantamab | Reimbursement Review | Complete | PC0289-000 | ||||
| Privately Operated Medical Imaging Facilities Across Canada | Health Technology Review | CMII Service | Completed | CM0007-000 | |||
| olaparib | Reimbursement Review | Complete | PC0299-000 | ||||
| Cognitive Health Assessment Management Platform | Horizon Scan | Health Technology Update | Completed | EN0046-000 | |||
| Prostate cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0023-000 | |||
| durvalumab | Reimbursement Review | Complete | PC0296-000 |